MCID: HYP080
MIFTS: 49

Hypogonadism

Categories: Endocrine diseases

Aliases & Classifications for Hypogonadism

MalaCards integrated aliases for Hypogonadism:

Name: Hypogonadism 12 73 29 54 44 15 70

Classifications:



External Ids:

Disease Ontology 12 DOID:1924
MeSH 44 D007006
NCIt 50 C9227
SNOMED-CT 67 48130008
UMLS 70 C0020619

Summaries for Hypogonadism

Disease Ontology : 12 A gonadal disease that is characterized by diminished functional activity of the gonads.

MalaCards based summary : Hypogonadism is related to hypogonadotropic hypogonadism 1 with or without anosmia and hypogonadism, male. An important gene associated with Hypogonadism is GNRH1 (Gonadotropin Releasing Hormone 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Dopamine and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and prostate, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 73 Hypogonadism means diminished functional activity of the gonads—the testes or the ovaries—that may... more...

Related Diseases for Hypogonadism

Diseases related to Hypogonadism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 911)
# Related Disease Score Top Affiliating Genes
1 hypogonadotropic hypogonadism 1 with or without anosmia 33.0 FGFR1 ANOS1
2 hypogonadism, male 32.7 LHCGR LHB
3 hypogonadotropic hypogonadism 7 with or without anosmia 32.6 SPRY4 PROKR2 POLR3B GNRHR GNRH1 FGFR1
4 adrenal hypoplasia, congenital 32.6 NR0B1 GNRHR GNRH1
5 hypogonadotropic hypogonadism 23 without anosmia 32.6 PROKR2 LHB GNRHR GNRH1 ANOS1
6 isolated gonadotropin-releasing hormone deficiency 32.5 GNRHR GNRH1
7 congenital hypogonadotropic hypogonadism 31.9 KISS1R GNRHR FGFR1 DUSP6 CHD7 ANOS1
8 kallmann syndrome 31.7 TACR3 TAC3 SPRY4 PROKR2 NSMF NR0B1
9 premature menopause 31.7 NR0B1 LHCGR KISS1R KISS1 GNRHR GNRH1
10 charge syndrome 31.4 TACR3 TAC3 PROKR2 KISS1R GNRHR GNRH1
11 46,xy sex reversal 31.4 NSMF NR0B1 LHCGR KISS1R GNRHR GNRH1
12 hypogonadotropic hypogonadism 31.3 TACR3 TAC3 SPRY4 PROKR2 POLR3B NSMF
13 penis agenesis 31.2 LHCGR GNRH1
14 amenorrhea 31.1 LHCGR LHB GNRHR GNRH1 FSHB
15 hypopituitarism 31.0 PROKR2 GNRH1 FSHB
16 normosmic congenital hypogonadotropic hypogonadism 31.0 TACR3 TAC3 SPRY4 PROKR2 POLR3B NSMF
17 infertility 30.9 TAC3 LHCGR LHB KISS1 GNRHR GNRH1
18 male infertility 30.7 LHCGR LHB GNRH1 FSHB
19 precocious puberty 30.7 LHCGR KISS1R KISS1 GNRH1
20 coloboma of macula 30.6 TACR3 PROKR2 GNRHR FGFR1 CHD7 ANOS1
21 cryptorchidism, unilateral or bilateral 30.4 TACR3 TAC3 SPRY4 PROKR2 NSMF NR0B1
22 ovarian hyperstimulation syndrome 30.4 LHCGR GNRH1 FSHB
23 anovulation 30.4 KISS1 GNRH1 FSHB
24 pseudohermaphroditism 30.3 NR0B1 LHCGR LHB
25 choanal atresia, posterior 30.2 TACR3 PROKR2 NSMF FGFR1 CHD7 ANOS1
26 central precocious puberty 30.1 KISS1R KISS1 GNRH1
27 pituitary stalk interruption syndrome 30.0 PROKR2 NSMF KISS1R CHD7
28 renal hypodysplasia/aplasia 1 29.9 TACR3 TAC3 SPRY4 PROKR2 NSMF KISS1R
29 septooptic dysplasia 29.7 PROKR2 NSMF GNRHR GNRH1 FGFR1 ANOS1
30 sensorineural hearing loss 29.7 TACR3 TAC3 PROKR2 NSMF GNRHR GNRH1
31 disorder of sexual development 29.5 PROKR2 NR0B1 LHCGR KISS1 GNRHR GNRH1
32 boucher-neuhauser syndrome 11.6
33 woodhouse-sakati syndrome 11.6
34 gordon holmes syndrome 11.6
35 cardiomyopathy, dilated, with hypergonadotropic hypogonadism 11.6
36 hypogonadotropic hypogonadism 21 with or without anosmia 11.5
37 hypogonadotropic hypogonadism 15 with or without anosmia 11.5
38 hypogonadotropic hypogonadism 5 with or without anosmia 11.5
39 hypogonadotropic hypogonadism 10 with or without anosmia 11.5
40 hypogonadotropic hypogonadism 8 with or without anosmia 11.5
41 hypogonadotropic hypogonadism 12 with or without anosmia 11.5
42 hypogonadotropic hypogonadism 11 with or without anosmia 11.5
43 hypogonadotropic hypogonadism 20 with or without anosmia 11.5
44 hypogonadotropic hypogonadism 14 with or without anosmia 11.5
45 hypogonadotropic hypogonadism 13 with or without anosmia 11.5
46 hypogonadotropic hypogonadism 16 with or without anosmia 11.5
47 hypogonadotropic hypogonadism 2 with or without anosmia 11.5
48 hypogonadotropic hypogonadism 9 with or without anosmia 11.5
49 hypogonadotropic hypogonadism 4 with or without anosmia 11.5
50 hypogonadotropic hypogonadism 6 with or without anosmia 11.5

Graphical network of the top 20 diseases related to Hypogonadism:



Diseases related to Hypogonadism

Symptoms & Phenotypes for Hypogonadism

GenomeRNAi Phenotypes related to Hypogonadism according to GeneCards Suite gene sharing:

26 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.62 KISS1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-126 9.62 FGFR1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-137 9.62 KISS1R
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.62 FGFR1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-15 9.62 KISS1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 9.62 KISS1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-169 9.62 KISS1R LHB
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.62 LHB
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.62 KISS1R
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-199 9.62 LHB
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 9.62 KISS1R
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-205 9.62 KISS1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.62 LHB
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.62 FGFR1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.62 LHB
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-57 9.62 KISS1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.62 KISS1R
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 9.62 FGFR1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.62 LHB

MGI Mouse Phenotypes related to Hypogonadism:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.1 CHD7 FGFR1 FSHB GNRH1 GNRHR KISS1
2 digestive/alimentary MP:0005381 9.97 CHD7 FGFR1 GNRH1 GNRHR KISS1 KISS1R
3 growth/size/body region MP:0005378 9.97 CHD7 DUSP6 FGFR1 GNRH1 GNRHR KISS1
4 homeostasis/metabolism MP:0005376 9.86 CHD7 DUSP6 FGFR1 FSHB GNRH1 GNRHR
5 reproductive system MP:0005389 9.5 CHD7 DCAF17 FGFR1 FSHB GNRH1 GNRHR

Drugs & Therapeutics for Hypogonadism

Drugs for Hypogonadism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
2
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
3
Liraglutide Approved Phase 4 204656-20-2 44147092
4
Dihydrotachysterol Approved Phase 4 67-96-9 5311071 5281010
5
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
6
Zinc Approved, Investigational Phase 4 7440-66-6 32051
7
Nutmeg Approved Phase 4
8
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
9
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
10
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
11 Fenugreek seed meal Phase 4
12 Fenugreek Phase 4
13 Neurotransmitter Agents Phase 4
14 Antidepressive Agents Phase 4
15 Psychotropic Drugs Phase 4
16 Dopamine Agents Phase 4
17 Serotonin Receptor Agonists Phase 4
18 Serotonin 5-HT1 Receptor Agonists Phase 4
19 Dopamine agonists Phase 4
20 Antipsychotic Agents Phase 4
21 Dopamine Antagonists Phase 4
22 Vitamin D2 Phase 4
23 Ergocalciferols Phase 4
24 Incretins Phase 4
25 Contraceptive Agents Phase 4
26 Triptorelin Pamoate Phase 4
27 Mace Phase 4
28 Aromatase Inhibitors Phase 4
29 Pharmaceutical Solutions Phase 4
30 Follicle Stimulating Hormone Phase 4
31 Vasodilator Agents Phase 4
32 Phosphodiesterase 5 Inhibitors Phase 4
33 Phosphodiesterase Inhibitors Phase 4
34 Vardenafil Dihydrochloride Phase 4
35
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
36
Dutasteride Approved, Investigational Phase 3 164656-23-9 6918296 152945
37
Metformin Approved Phase 3 657-24-9 4091 14219
38
Alendronate Approved Phase 3 121268-17-5, 66376-36-1 2088
39
tannic acid Approved Phase 3 1401-55-4
40
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
41
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
42
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
43
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 8001-79-4
44
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
45
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221
46
Dihydrotestosterone Illicit, Investigational Phase 3 521-18-6 10635
47 5-alpha Reductase Inhibitors Phase 3
48 Anabolic Agents Phase 3
49 Antineoplastic Agents, Hormonal Phase 3
50 Chelating Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 325)
# Name Status NCT ID Phase Drugs
1 Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin is Superior to Human Chorionic Gonadotropin in Therapeutic Efficacy in Adolescent Boys With Congenital Hypogonadotropic Hypogonadism Unknown status NCT02880280 Phase 4 Human Menopausal Gonadotropin;Human Chorionic Gonadotropin
2 Effect of Androgel on Inflammatory Mediators and Oxidative Stress in Type 2 Diabetic Males With Hypogonadism Unknown status NCT00350701 Phase 4 androgel;androgel 10g;placebo
3 Study on the Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism Unknown status NCT02310074 Phase 4 Pulsatile Gonadotropin Releasing Hormone;Human chorionic gonadotropin;Urinary Follicle-Stimulating Hormone
4 Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation by Using Recombinant Luteinizing Hormone (rLH) and Recombinant Follicle Stimulating Hormone (rFSH) in Patients With Hypogonadotropic Hypogonadism Unknown status NCT02140515 Phase 4 Lutropin alfa;Follitropin alfa and Lutropin alfa
5 The Efficacy of Testosterone Replacement in Treating Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
6 Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate i.m. 1000 mg. A Prospective, Multi-Center Clinical Study Phase IV. Unknown status NCT00555087 Phase 4 Testosterone Undecanoate and/or PDE-5
7 The Effect of Testim and Training in a Population Based, Randomized, Placebo-controlled, Double-blinded Study of Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
8 Testosterone Replacement and Dutasteride Effectiveness (TRADE) Completed NCT00194675 Phase 4 Dutasteride;Testosterone gel;Placebo dutasteride
9 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
10 Phase 4 Study That Compares the High Density Lipoprotein Cholesterol (HDL) Cholesterol Subgroups of the Patients With Congenital Hypogonadotrophic Hypogonadism With That of the Healthy Control Subjects, and Investigates the Effect of Testosterone Treatment on HDL Subgroups. Completed NCT01454011 Phase 4 Testosteron 250mg injection;Testosterone 50mg transdermal application
11 Effect of Hypogonadotrophic Hypogonadism and Treatment With Testosterone on Insulin Sensitivity, Inflammation, Body Composition and Sexual Function in Obese and Type 2 Diabetic Men Completed NCT01127659 Phase 4 testosterone;placebo
12 Phase IV Study to Investigate the Effect of Testosterone Treatment on Paraoxonase Level in Male Patients With Hypogonadotrophic Hypogonadism Completed NCT01107067 Phase 4 Sustanon
13 Aripiprazole Treatment for Antipsychotic Induced Hyperprolactinaemia in Patients With Severe Mental Illness and Learning Disabilities Completed NCT01085383 Phase 4 Aripiprazole
14 A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Androgen Levels in Hypogonadal Men Completed NCT01748370 Phase 4 Vitamin D supplementation in hypogonadal men;Vitamin D supplementation in eugonadal men;Placebo hypogonadal;Placebo eugonadal
15 Effects of Three Different Medications on Metabolic Parameters and Testicular Volume in Patients With Hypogonadotropic Hypogonadism-Last Three Years Experience Completed NCT01601327 Phase 4 Testosterone enanthate (Sustanon 250 mg);Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU);Testosteron gel (Testojel 50 mg)
16 Effects of Liraglutide and Testosterone Replacement Therapy on Features of Hypogonadism and Weight Loss in Obese Men With Persistent Features of Hypogonadism. Completed NCT03619330 Phase 4 liraglutide;Testosterone
17 Xiaflex® Plus Testosterone Treatment Pilot Study Protocol A Six-month, Pilot Project of Testosterone Treatment in Subjects Who Are Undergoing Xiaflex® Therapy for the Treatment of Peyronie's Disease Completed NCT03815331 Phase 4 Xiaflex®;Aveed
18 Effects of Testosterone on Myocardial Repolarization in Patients With Hypogonadism With/Without Chronic Heat Failure (NYHA Class I-II) Completed NCT03126656 Phase 4 Testosterone Undecanoate
19 The Effect of Testosterone Replacement in Patients With Hypogonadotrophic Hypogonadism Due to Opioid Treatment for Non-malignant Disease Completed NCT02433730 Phase 4 Testosterone;placebo
20 Efficacy and Safety of Human Chorionic Gonadotropin (HCG) and Follicle Stimulating Hormone (FSH) in the Treatment of Hypogonadotropic Hypogonadism Completed NCT01403532 Phase 4 Traditional intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH plus zinc
21 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
22 Phase 4 Study That Evaluates the Presence of Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Subjects With Hypogonadotrophic Hypogonadism and Effects of Two Different Testosterone Replacement Regiments on These Parameters. Completed NCT02171390 Phase 4 Testosterone 250mg injection;Testosteron 50 mg transdermal gel
23 Phase 4 Study of Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism Completed NCT02111473 Phase 4 Testosterone
24 A 150-Day, Prospective, Phase 4, Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Testosterone Nasal Gel (Natesto™) Completed NCT02937740 Phase 4 NATESTO Testosterone Nasal Gel
25 Phase 4 Study That Evaluates the Effects of Two Different Testosterone Replacement Regiments on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Subjects With Hypogonadotrophic Hypogonadism. Completed NCT01533129 Phase 4 Testogel 50 mg transdermal gel;Testosterone 250mg injection
26 Phase 4 Study of Effect of Testosteron Treatment on the Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism Completed NCT02111434 Phase 4 Testosterone
27 A Randomised, Double Blind, Placebo-controlled Parallel Study to Test the Effect of Testosterone Treatment on Peripheral Vascular Disease in Hypogonadal Men With Type 2 Diabetes Mellitus Completed NCT00355537 Phase 4 Testosterone;0.9% saline
28 Effect of Testosterone Replacement on Insulin Resistance in Hypogonadal, Non-obese Men With Metabolic Syndrome Completed NCT00487734 Phase 4 Placebo for testosterone gel
29 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Completed NCT02959853 Phase 4 Anastrazole
30 Effectiveness of Testosterone Replacement Therapy (TRT) on Prostatic Gland in Hypogonadal Patients Affected by Benign Prostatic Hyperplasia (BPH) and Metabolic Syndrome (MetS). Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%
31 The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel Completed NCT01893281 Phase 4 Topical Testosterone Solution
32 Phase IV Study of The Therapy of Long-acting Testosterone Undecanoate,1000mg in 4 ml Oily Solution for i.m.Injection(Nebido) as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction Completed NCT00421460 Phase 4 Testosterone Undecanoate,1000mg
33 A Randomised Double Blind Placebo Controlled, Parallel Pilot Study to Test the Effect of Testosterone Replacement on Glycaemic Control and Arterial Wall Properties of Hypogonadal Men With Type 2 Diabetes Treated With Insulin Completed NCT00349362 Phase 4 Testosterone;0.9% saline
34 A Randomised, Double Blind, Placebo Controlled, Parallel Pilot Study to Test the Effect of Testosterone Treatment on Peripheral Vascular Disease in Hypogonadal Men With Type 2 Diabetes Mellitus Completed NCT00504712 Phase 4 Testosterone;saline
35 Effects of Testosterone Replacement on Atherosclerosis Progression in Older Men With Low Testosterone Levels Completed NCT00287586 Phase 4 Testosterone Gel (Androgel);Placebo
36 Phase 4 Study of About the Effect of Testosterone Treatment on the Components of Metabolic Syndrome Completed NCT01160341 Phase 4 Testosteron
37 Testosterone Replacement in Metabolic Syndrome and Inflammation of Fat Tissue Completed NCT01123278 Phase 4 Testosterone;Placebo
38 Efficacy and Safety of a Mixed Extract of Fenugreek Seed and Lespedeza Cuneata in the Treatment of Testosterone Deficiency Syndrome: A Randomized, Double-blind, Placebo-Controlled Clinical Trial Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
39 Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Completed NCT03203681 Phase 4 Natesto
40 Dutasteride in Men Receiving Testosterone Therapy: Impact on Serum PSA, Testosterone, DHT Levels and Prostate Volume: "Implications for Prostate Safety" Completed NCT00752869 Phase 4 dutasteride;placebo
41 Subcutaneous Testosterone Therapy in Men Compared to Intramuscular Testosterone Therapy in Men Completed NCT03091348 Phase 4 Testosterone
42 Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM) - a Randomised, Doubleblinded and Placebocontrolled Trial of Men With Subnormal Testosterone Levels and T2DM. Completed NCT01560546 Phase 4 Testosterone;Placebo
43 Estrogen Dosing in Turner Syndrome:Pharmacology & Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
44 Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) Study Recruiting NCT03518034 Phase 4 Testosterone;Placebo
45 Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism Recruiting NCT03887936 Phase 4 Testosterone gel 1.62%;Placebo
46 Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in the Treatment of Male Patients With Isolated Hypogonadotropic Hypogonadism: an Open, Randomized Controlled Study Recruiting NCT03687606 Phase 4 Human Chorionic Gonadotropin;human menopausal gonadotropin
47 Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism Recruiting NCT03490513 Phase 4 anastrozole (1 mg/day);Placebo
48 An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Administration With Marketed Testosterone Products Recruiting NCT04456296 Phase 4 Aveed Injectable Product, Fortesta or Testim
49 A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections: A Phase IV, Prospective, Randomized, Non-Blinded, Multi-Institutional Study Recruiting NCT04439799 Phase 4 Testosterone Cypionate 200 MG/ML;Intranasal Testosterone
50 A Phase IV, Multi-center, Open-label, Single-arm 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Study of 16 Weeks Treatment With Androderm® in Hypogonadal Men Recruiting NCT04320745 Phase 4 Androderm®

Search NIH Clinical Center for Hypogonadism

Inferred drug relations via UMLS 70 / NDF-RT 51 :


2-Bromoergocryptine Mesylate
Black Cohosh Extract
Bromocriptine
Chlorotrianisene
Estradiol
Estradiol acetate
estradiol cypionate
ESTRADIOL PWDR
estradiol valerate
Estrogens
Estrogens, Conjugated (USP)
Estrogens, Esterified (USP)
Estrone
estropipate
Ethinyl Estradiol
Ethynodiol Diacetate
Fluoxymesterone
Methyltestosterone
METHYLTESTOSTERONE PWDR
Norethindrone
norethindrone acetate
polyestradiol
polyestradiol phosphate
Sodium estrone sulfate
synthetic conjugated estrogens, A
synthetic conjugated estrogens, B
Testosterone
testosterone cypionate
testosterone enanthate
Testosterone Propionate
TESTOSTERONE PROPIONATE PWDR
TESTOSTERONE PWDR
testosterone undecanoate

Cochrane evidence based reviews: hypogonadism

Genetic Tests for Hypogonadism

Genetic tests related to Hypogonadism:

# Genetic test Affiliating Genes
1 Hypogonadism 29

Anatomical Context for Hypogonadism

MalaCards organs/tissues related to Hypogonadism:

40
Pituitary, Bone, Prostate, Liver, Brain, Testis, Testes

Publications for Hypogonadism

Articles related to Hypogonadism:

(show top 50) (show all 10873)
# Title Authors PMID Year
1
Novel insights in FGFR1 regulation: lessons from Kallmann syndrome. 61 54
20117945 2010
2
Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality. 61 54
19656574 2010
3
[Case of progressive prostatic carcinoma in a patient with acquired hypogonadism]. 61 54
20448451 2010
4
A new FSHbeta mutation in a 29-year-old woman with primary amenorrhea and isolated FSH deficiency: functional characterization and ovarian response to human recombinant FSH. 61 54
19966036 2010
5
Management of erectile dysfunction. 54 61
20112889 2010
6
Recombinant follitropin alfa/lutropin alfa in fertility treatment. 61 54
20161981 2010
7
Narrative review: the role of leptin in human physiology: emerging clinical applications. 54 61
20083828 2010
8
The relationship of testosterone to prostate-specific antigen in men with sexual dysfunction. 61 54
19912506 2010
9
Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. 61 54
19226407 2009
10
Prostate cancer and acromegaly. 61 54
20126848 2009
11
Relationship between insulin and hypogonadism in men with metabolic syndrome. 54 61
20126854 2009
12
Adiponectin and testosterone in patients with symptoms of late-onset hypogonadism: is there a link? 54 61
19719531 2009
13
Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa. 54 61
19523548 2009
14
Dimeric PROP1 binding to diverse palindromic TAAT sequences promotes its transcriptional activity. 54 61
19524124 2009
15
Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism. 61 54
19458139 2009
16
Peptide YY in adolescent athletes with amenorrhea, eumenorrheic athletes and non-athletic controls. 54 61
19344792 2009
17
Bone mineral density and disorders of mineral metabolism in chronic liver disease. 54 61
19630107 2009
18
The emerging link between hypogonadism and metabolic syndrome. 61 54
18772486 2009
19
Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. 61 54
19154450 2009
20
Androgen receptor roles in spermatogenesis and fertility: lessons from testicular cell-specific androgen receptor knockout mice. 61 54
19176467 2009
21
Leptin: a pivotal regulator of human energy homeostasis. 61 54
19211814 2009
22
Non-functioning pituitary adenomas: clinical feature, laboratorial and imaging assessment, therapeutic management and outcome. 61 54
19347183 2009
23
Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. 61 54
19156143 2009
24
Inactivating mutations of luteinizing hormone beta-subunit or luteinizing hormone receptor cause oligo-amenorrhea and infertility in women. 61 54
19129711 2009
25
Has prolactin a role in the hypogonadal status of HIV-infected patients? 54 61
19171915 2009
26
FSHbeta gene mutation in a female with delayed puberty and hypogonadism: response to recombinant human FSH. 61 54
20067895 2009
27
Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients. 54 61
18854428 2008
28
Laboratory diagnosis of late-onset male hypogonadism andropause. 61 54
19197450 2008
29
Left ventricular dysfunction in Klinefelter syndrome is associated to insulin resistance, abdominal adiposity and hypogonadism. 54 61
18248650 2008
30
Relationship of prostate-specific antigen to age and testosterone in men with type 2 diabetes mellitus. 54 61
19095599 2008
31
Testosterone and erectile dysfunction. 54 61
18641415 2008
32
Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). 54 61
18429947 2008
33
[Long-term steroid therapy in children: is adjunct therapy relevant in nephrotic syndrome?]. 61 54
18951767 2008
34
Acylated ghrelin and leptin in adolescent athletes with amenorrhea, eumenorrheic athletes and controls: a cross-sectional study. 61 54
18331605 2008
35
[Testosterone replacement in hypogonadotropic hypogonadal young male improves insulin sensitivity]. 54 61
19080648 2008
36
Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. 54 61
18449947 2008
37
Kisspeptin and GPR54: discovery of a novel pathway in reproduction. 61 54
18601695 2008
38
Bone density in the adolescent athlete. 54 61
18409004 2008
39
Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. 61 54
18195686 2008
40
The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. 61 54
18343420 2008
41
Prevalence of androgen deficiency in men with erectile dysfunction. 54 61
18313109 2008
42
[Phenotype of patients with gynecomastia]. 54 61
18465688 2008
43
Secondary hypothyroidism in hereditary hemochromatosis: recovery after iron depletion. 61 54
18205549 2008
44
Seminiferous tubule function in delayed-onset X-linked adrenal hypoplasia congenita associated with incomplete hypogonadotrophic hypogonadism. 54 61
17803711 2008
45
The role of cyclase activating (CAP) and cyclase inhibiting (CIP) parathormone fractions in the assessment of bone metabolism disturbances in women with hyperprolactinemia of various origin. 61 54
18283239 2008
46
[Pathogenetically complicated case of osteoporosis in a young man]. 54 61
19097362 2008
47
Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system. 61 54
19554077 2008
48
Metabolic syndrome and reproduction: I. testicular function. 54 61
18224542 2008
49
Cholestasis and metabolic bone disease - a clinical review. 61 54
18998071 2008
50
The complex genetics of Kallmann syndrome: KAL1, FGFR1, FGF8, PROKR2, PROK2, et al. 61 54
18987492 2008

Variations for Hypogonadism

Expression for Hypogonadism

Search GEO for disease gene expression data for Hypogonadism.

Pathways for Hypogonadism

Pathways related to Hypogonadism according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 TACR3 TAC3 PROKR2 LHCGR LHB KISS1R
2
Show member pathways
13.14 TACR3 TAC3 PROKR2 LHCGR LHB KISS1R
3
Show member pathways
12.32 LHB GNRHR GNRH1 FSHB
4 12.05 TACR3 LHCGR FGFR1 FGF17
5
Show member pathways
11.97 LHB GNRH1 FGFR1 FGF17
6 11.82 LHCGR LHB FSHB
7 11.4 LHB GNRH1 FGFR1 FGF17
8 11.21 LHCGR LHB FSHB
9 11.06 LHB KISS1R KISS1 GNRH1
10 10.14 LHCGR LHB GNRHR GNRH1 FSHB

GO Terms for Hypogonadism

Biological processes related to Hypogonadism according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.1 TACR3 PROKR2 LHCGR LHB KISS1R GNRHR
2 male gonad development GO:0008584 9.65 NR0B1 LHCGR LHB
3 neuropeptide signaling pathway GO:0007218 9.63 TAC3 PROKR2 KISS1R
4 female pregnancy GO:0007565 9.61 TAC3 GNRH1 FSHB
5 fibroblast growth factor receptor signaling pathway GO:0008543 9.58 FGFR1 FGF17 ANOS1
6 positive regulation of blood pressure GO:0045777 9.52 TACR3 TAC3
7 peptide hormone processing GO:0016486 9.51 LHB FSHB
8 male sex determination GO:0030238 9.37 NR0B1 GNRH1
9 hormone-mediated signaling pathway GO:0009755 9.33 LHCGR LHB FSHB
10 cellular response to gonadotropin stimulus GO:0071371 9.32 NSMF LHCGR
11 G protein-coupled receptor signaling pathway GO:0007186 9.32 TACR3 TAC3 PROKR2 LHCGR LHB KISS1R
12 tachykinin receptor signaling pathway GO:0007217 9.26 TACR3 TAC3
13 progesterone biosynthetic process GO:0006701 8.96 LHB FSHB

Molecular functions related to Hypogonadism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.13 LHB GNRH1 FSHB
2 protein-hormone receptor activity GO:0016500 8.62 LHCGR GNRHR

Sources for Hypogonadism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....